

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>				Complete If Known
				Application Number 10/550,518 Filing Date September 23, 2005 First Named Inventor BACHMANN, Martin F. Art Unit 1633 Examiner Name LI, Qian Janice Attorney Docket Number 1700.0630000/BJD/WBC
Sheet	1	of	1	

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ Date Considered _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M PER 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next examination, if applicable. _____, Acacipot's unique citation designation/no. (optional) _____ See Kindi_Collect at USPTO. Print, Drawsearch or www.uspto.gov/mper/MPER001-04.shtm

³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Transaction is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1633
				Examiner Name	LI, Qian Janice
Sheet	1	of	2	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	NPL179	Ashcroft, <i>et al.</i> (2003) Immunity 19(6):849-61 -- Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Cell Press.			
	NPL180	Axblom, <i>et al.</i> (1998) Virology 249(NA):80-8 -- Structure of Phage fr capsids with a Deletion in the FG loop: Implications for Viral Assembly. Academic Press.			
	NPL181	Azuma (1992) Vaccine 10(14):1000-6 -- Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Elsevier Science.			
	NPL182	Bird (1987) TIG 3(12):342-347 -- CpG islands as gene markers in the vertebrate nucleus. Elsevier Trends Journals.			
	NPL183	Branda, <i>et al.</i> (1993) Biochem Pharmacol 45(10):2037-43 -- Immune stimulation by an antisense oligomer complementary to the <i>rev</i> gene of HIV-1. Elsevier Science.			
	NPL184	Francois, <i>et al.</i> (1988) Clin Immunol Immunopathol 48(3):297-306 -- Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. Academic Press.			
	NPL185	Gilkeson, <i>et al.</i> (1989) Clin Immunol Immunopathol 51(3):362-71 -- The antibody response of normal mice to immunization with single-stranded DNA of various species origin. Academic Press.			
	NPL186	Holt (1994) Lancet 344(8920):456-8 -- A potential vaccine strategy for asthma and allied atopic diseases during early childhood. Lancet Publishing Group.			
	NPL187	Kataoka, <i>et al.</i> (1988) Jpn J Cancer Res 79(7):817-20 -- A synthetic adjuvant effective in inducing antitumor immunity. Japanese Cancer Association.			
	NPL188	Lotz, <i>et al.</i> (1987) J Rheumatol 14(1):42-5 -- Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus. Journal Of Rheumatology Publishing Co.			
	NPL189	McIntyre, <i>et al.</i> (1993) Antisense Res Dev 3(4):309-22 -- A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. Mary Ann Liebert.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
				Application Number	10/550,518
				Filing Date	September 23, 2005
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1633
				Examiner Name	LI, Qian Janice
Sheet	2	of	2	Attorney Docket Number	1700.0630000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	NPL190	Merritt, <i>et al.</i> (1965) J Immunol 94(3):416-22 -- Studies on the Adjuvant action of bacterial endotoxins on antibody formation. VI. Enhancement of Antibody formation by nucleic acids. American Association of Immunologists.			
	NPL191	Messina, <i>et al.</i> (1991) J Immunol 147(6):1759-64 -- Stimulation of <i>in vitro</i> murine lymphocyte proliferation by bacterial DNA. American Association of Immunologists.			
	NPL192	Messina, <i>et al.</i> (1993) Cell Immunol 147(1):148-57 -- The influence of DNA structure on the <i>in vitro</i> stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Academic Press.			
	NPL193	Mojcik, <i>et al.</i> (1993) Clin Immunol Immunopathol 67(2):130-6 -- Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF <i>env</i> causes immune effects <i>in vivo</i> in a sequence-specific manner. Academic Press.			
	NPL194	Nohria, <i>et al.</i> (1994) Biotherapy 7(3-4):261-9 -- Cytokines as potential vaccine adjuvants. Kluwer Academic Publishers.			
	NPL195	Peabody (1997) Arch Biochem Biophys 347(1):85-92 -- Subunit fusion confers tolerance to peptide insertions in a virus coat protein. Academic Press.			
	NPL196	Pisetsky, <i>et al.</i> (1993) Mol Biol Rep 18(3):217-21 -- Stimulation of <i>in vitro</i> proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Reidel.			
	NPL197	Saiki, <i>et al.</i> (1988) Vaccine 6(3):238-44 -- Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues. Elsevier Science.			
	NPL198	Stonehouse, <i>et al.</i> (1993) FEBS Lett 334(3):355-9 -- Effects of amino acid substitution on the thermal stability of MS2 capsids lacking genomic RNA. Elsevier Science.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.